Efeitos do monoterpeno (-)-mirtenol sobre o Sistema Nervoso Central: estudos in vitro e in vivo

• Autor(a) principal: Moreira, Maria Rosilene Candido
• Data de Publicação: 2013
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UFPB
• Texto Completo: https://repositorio.ufpb.br/jspui/handle/tede/343
• topic: Mirtenol; Ansiolítico; Antioxidante; Neuroléptico; Anticonvulsivante; Sistema nervoso central; Monoterpeno; Óleos essenciais; (-)-myrtenol; Anxiolytic; Antioxidant; Neuroleptic; Central nervous system; Monoterpene; Essential oils; CIENCIAS BIOLOGICAS

(-)-myrtenol (MYR) is a monoterpene found in various aromatic plants. However, te scientific literature has not yet described any psychopharmacological properties of this molecule. This study aimed to investigate the influence of myrtenol on the central nervous system of male Swiss mice and Wistar rats checking their anxiolytic, neuroleptic and anticonvulsant activities, in addition to its antioxidant and toxic potentials. Anxiolytic assays were performed using the elevated plus maze test (EPM) and light-dark transition test (LDT), besides the open field test (OFT) and Rota Rod test to assess the effects on the locomotor system of these animals. The neuroleptic activity was checked by the test of catalepsy induced by haloperidol (HAL). The anticonvulsant effect was analyzed by seizures induced by pentylenetetrazol (PTZ), picrotoxin (PIC) and pilocarpine (P). To check the potential toxicity hippocratic screening was performed, by assessment of body weight, food consumption and production of excreta, the hematological and biochemical parameters, as well as macroscopic and histopathological organs of experimental animals. Additionally, was studied the antioxidant profile the study on the antioxidant profile, through in vitro (TBARS, removal of nitrite and hydroxyl radical) and in vivo techniques [lipid peroxidation, nitrite production and activity of catalase (CAT), superoxide dismutase (SOD) and reduced glutathione (GSH)]. In EPM, myrtenol administration significantly increased the input numbers (MYR=5.6; Control=3.1) and time spent by the animals in the open arms (MYR=106.8s; Control=47.5s) when compared with the control group and in the LDT myrtenol increased significantly the time spent by animals in the light compartment (MYR=187.4s; Control=105.1s). In OFL and Rota Rod test, the results revealed no significant changes in the parameters observed. In seizures induced, the results revealed that the myrtenol increased the latency to the first seizure [P(MYR=21.5s; Control=11.9s); PTZ(MYR=280.4s; Control=87.3s); PIC(MYR=696.0s; Control=522.4s)] and decreased the percentage of seizures [P(MYR=53.3%;); PTZ(MYR=37.3%); PIC(MYR=33.3%)], as well as the percentage of deaths of animals [P(MYR=53.3%); PTZ(MYR=48.3%); PIC(MYR=33.3%)]. The test of catatonia showed a significant reduction in the time spent in the antiphysiologic position (MYR=0.9s; HAL=29.7s). On the toxicity studies, the hippocratic screening showed good tolerability of myrtenol and no significant changes in dietary patterns, production of excreta, body weight, hematological and biochemical parameters and morphological or histopathological findings. About the antioxidant potential, myrtenol reduced lipid peroxidation (MYR=86.8%; VitC=56%), level of nitrite (MYR=85.3%; VitC=24.5%) and increased antioxidants enzymes activity [CAT(MYR=102.3%; SOD (MYR=39.5%); GSH(MYR=12.2%)] in treated animals. In conclusion, myrtenol has anxiolytic potential without sedative effect, possesses neuroleptic, anticonvulsant and antioxidant activities, with low toxicity and can be considered a potential bioproduct in formulation of phytomedicine.